Psychedelic Healthcare: The Next Five Years
This week COMPASS Pathways provided an eagerly anticipated update from its Phase IIb clinical trial. The largest ever study with psilocybin comprised 233 patients and found a single dose of psilocybin, given in conjunction with psychological support, rapidly reduced symptoms of depression.
Globally there are over 80 active Phase II trials with psychedelic medicines, with MAPS’ MDMA formulation to treat PTSD the furthest along in the approval process. The company expects regulatory approval in North America by late 2023, and in Europe by the fourth quarter of 2024.Read More